Literature DB >> 27272475

"Drug-resistant granuloma faciale": treatment with carbon dioxide-GaAs laser.

Andrea Paradisi1, Francesco Ricci2, Paolo Sbano3.   

Abstract

Granuloma faciale (GF), also known as "eosinophilic granuloma," is a rare benign leukocytoclastic vasculitis which most commonly occurs on the face of middle-aged Caucasian males. Clinically, GF appears as single or multiple, slowly growing, reddish-brown papules, nodules or plaques which may be cosmetically unpleasant. Its pathogenesis is unknown and GF is notoriously resistant to treatments. Both medical (dapsone, colchicine, gold injections, isoniazid, clofazimine, corticosteroids, psoralen ultraviolet radiation, and topical tacrolimus) and surgical therapies (excision, graft, dermabrasion, argon laser, carbon dioxide laser, pulsed dye laser, cryotherapy, and electrosurgery) have been used for GF but no effective treatment has yet been found. Furthermore, the typical facial location of GF requires an acceptable cosmetic result. We report two cases of drug-resistant GF which were successfully treated with laser vaporization combining two different wavelengths: carbon dioxide (CO2 ) 10,600 nm and GaAs 1540 nm.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  GaAs laser; carbon dioxide laser; granuloma faciale

Mesh:

Substances:

Year:  2016        PMID: 27272475     DOI: 10.1111/dth.12365

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide.

Authors:  Chunyu Yuan; Wenbo Bu; Xu Chen; Heng Gu
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

2.  Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Natalia Gil-Aliberas; Victor Garcia-Gimenez
Journal:  Immunol Res       Date:  2018-02       Impact factor: 4.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.